DURHAM, N.C. and EXTON, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the œCompany) (Nasdaq: ACGN), announced today that the Company intends to voluntarily terminate the listing of its...
DURHAM, N.C. and EXTON, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the œCompany) (Nasdaq: ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock...
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study
As biotechs start to detail 2023 plans — M&A, new emphases in drug R&D and more with investors — others are starting to trim back or using the new year as an opportunity to do an about-face and try and start with a clean slate.